Q-omics provides the consensus-scored METTL21EP profile across patient tissues and cancer cell-line models. METTL21EP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, METTL21EP is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, METTL21EP RNA expression shows 16,975 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where METTL21EP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL21EP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL21EP survival associations across molecular data types. METTL21EP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL21EP RNA expression–survival associations across cancer types. High METTL21EP expression shows favorable associations in MESO, LUAD, LGG, UCS, PAAD and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for METTL21EP RNA expression.
This table summarizes METTL21EP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for METTL21EP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL21EP shows lower tumor expression in HNSC, KICH, BRCA and LUSC and higher tumor expression in KIRC and COAD. The HNSC box plot shows higher METTL21EP RNA expression in normal versus tumor tissue (log2 FC = −1.512, t-test p < 0.001).
This table shows molecular features associated with METTL21EP in patient tissues and cancer cell lines. In patient samples, METTL21EP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
